GZMO Message Board - Msg: 11306903

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jeffbas who wrote (102)	9/20/1999 6:05:00 PM
From: scaram(o)uche	Read Replies (1) of 438

>> Rick, can you draw any inference that because ATIII is known to be safe for humans that aaATIII will also be safe << Jeff..... it's better than that. Certain preparations of plasma-derived ATIII actually contain aaAT. >> Is it good to have AS/ES ahead in the sense that if something is heard about the progress there, GZMO can take advantage of it, even to the extent of abandoning the project if this class of compounds is ineffective in humans? << I've always thought that there was no commercial viability to AS/ES, so this is a moot point to me. >> I noticed with interest the lower dosage required -- would this be such an "improvement"? << If mice were only human. But, the 10 mg/kg/day would be very "doable" IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next